|
Pfizer announces new Chief Scientific Officer and President, Research & Development
|
26 November 2024 |
|
U.S. FDA approves Pfizer's RSV vaccine ABRYSVO® for adults aged 18 to 59 at increased risk for disease
|
23 October 2024 |
|
Pfizer highlights diverse oncology oortfolio and combination approaches at ESMO 2024
|
11 September 2024 |
|
Pfizer launches PfizerForAll™, a digital platform that helps simplify access to healthcare
|
29 August 2024 |
|
Pfizer and BioNTech provide update on mRNA-based combination vaccine program against influenza and COVID-19 in individuals 18-64 years of age
|
20 August 2024 |
|
Pfizer announces top-line results of ABRYSVO® for RSV in immunocompromised adults
|
12 August 2024 |
|
Pfizer announces positive topline results From Phase 3 study of hemophilia A gene therapy candidate
|
24 July 2024 |
|
Pfizer advances development of once-daily formulation of oral GLP-1 receptor agonist danuglipron
|
16 July 2024 |
|
Pfizer's LORBRENA® CROWN study shows majority of patients with ALK-positive advanced lung cancer living beyond five years without disease progression
|
31 May 2024 |
|
U.S. FDA approves Pfizer's BEQVEZ™ (fidanacogene elaparvovec-dzkt), a one-time gene therapy for adults with Hemophilia B
|
26 April 2024 |
|
European Commission approves Pfizer's EMBLAVEO® for patients with multidrug-resistant infections and limited treatment options
|
22 April 2024 |
|
European Commission approves Pfizer's PREVENAR 20® to help protect infants and children against pneumococcal disease
|
13 March 2024 |
|
Pfizer announces positive top-line data for full season two efficacy of ABRYSVO® for RSV in older adults
|
29 February 2024 |
|
European Commission approves Pfizer's VELSIPITY® for patients with moderately to severely Active ulcerative colitis
|
23 February 2024 |
|
The American Cancer Society and Pfizer announce a $15 million, three-year initiative to bridge the gap in cancer care disparities
|
05 February 2024 |
|
Pfizer recommends shareholders reject the below-market mini-tender offer by TRC Capital Investment Corporation
|
18 January 2024 |
|
TIVDAK® supplemental Biologics License Application accepted for Priority Review by FDA for patients with recurrent or metastatic cervical cancer
|
10 January 2024 |
|
Pfizer declares first-quarter 2024 dividend
|
15 December 2023 |
|
Pfizer announces topline Phase 2b results of oral GLP-1R agonist, danuglipron, in adults with obesity
|
04 December 2023 |
|
Pfizer and Astellas' XTANDI® approved by U.S. FDA in earlier prostate cancer treatment setting
|
21 November 2023 |